What do the NICE guidelines say about Mounjaro?

What exactly does NICE TA1026 say about who qualifies?

NICE's appraisal of tirzepatide sets two headline conditions: a BMI of 35 or above, and at least one weight-related comorbidity from a defined list. The five conditions NICE identifies are high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, established cardiovascular disease, and type 2 diabetes. Meeting both thresholds is the starting point, not the finish line — suitability is still a clinical judgement made by a prescriber.

For adults from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold is 2.5 kg/m² lower throughout. NICE also specifies that treatment should be reviewed if a patient achieves less than 5% weight loss after six months at the highest tolerated dose. The full recommendation text is available on NICE's TA1026 guidance page, and it is worth reading the recommendations chapter directly rather than relying on summaries.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, it activates two gut-hormone pathways involved in appetite regulation and blood-sugar control, which distinguishes it from the single-pathway medicines that came before it. In the SURMOUNT-1 trial, participants at the 15 mg dose achieved an average body-weight reduction of around 20–21% over 72 weeks. If you want to understand how NICE weighed this evidence when forming its position, our page on NICE and Mounjaro walks through the committee's reasoning in detail.

How is NHS access to Mounjaro being phased in under the guidelines?

NICE recommending a medicine does not mean every eligible patient can collect it from their GP tomorrow. NHS England has staged rollout tied to strict cohort criteria. The first cohort (available from June 2025) requires a BMI of 40 or above and four or more of the five qualifying conditions. The second cohort, activated on 23 June 2026, opens access to adults with a BMI between 35 and 39.9 alongside four or more conditions. A further cohort requiring BMI of 40 or above with three conditions is expected around March 2027.

From 1 April 2026, GP practices can prescribe tirzepatide under the updated QOF contract, but participation is optional, so availability genuinely varies by practice and area. Every NHS patient is also expected to take part in wrap-around diet and activity support as part of treatment. Criteria qualifying you on paper do not guarantee a prescription; your GP must confirm you fit the active cohort. For a full breakdown of the prescribing standards GPs follow, our overview of UK tirzepatide prescribing guidelines covers the clinical framework in detail.

Scotland, Wales and Northern Ireland operate different access frameworks, thresholds and waiting times vary, so it is worth checking with your local health board rather than assuming the England cohort dates apply.

What about the Mounjaro guidelines on HRT and surgery?

NICE TA1026 focuses on clinical eligibility and review criteria rather than specific drug interactions, but NHS England's accompanying wraparound guidance addresses two questions that come up repeatedly in practice.

For women taking oral contraceptives, tirzepatide slows gastric emptying enough that absorption of the pill may be reduced during the first four weeks of treatment and for four weeks after each dose increase. NHS guidance recommends adding a non-oral method of contraception during those windows. There is no equivalent recommendation for semaglutide, which makes this point specific to tirzepatide. The NHS England weight-management injections page sets this out clearly alongside advice on HRT: transdermal options such as patches or gels are worth discussing with your doctor while on tirzepatide, for the same absorption reason.

On surgery, the guidance is clear: tell your healthcare team, including the anaesthetist, that you are taking tirzepatide before any procedure. This applies to planned and emergency operations alike. Our page on Mounjaro and anaesthesia covers what the guidelines say in full. It is also sensible to mention it to any prescriber adding a new medicine, since gastric-emptying effects can affect how other drugs are absorbed, a question our clinical team regularly fields. If you have questions about a specific medicine alongside tirzepatide, common interaction queries are covered separately.

If I don't meet the NHS criteria, what are my options?

Private treatment sits outside the NICE NHS-access pathway but still requires a genuine clinical assessment, the prescription-only status of tirzepatide does not change because you are paying privately. A GPhC-registered prescriber must review your health history, verify your weight and confirm suitability before any medicine is supplied.

The private eligibility criteria follow the licensed indication in the Mounjaro SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That is a meaningfully lower bar than the NICE NHS threshold of 35 plus four comorbidities, which is why many people who do not currently qualify for NHS access choose the private route. If you want to understand the full clinical picture before booking anything, our Mounjaro guide walks through how treatment works in practice, and our tirzepatide overview covers the mechanism and trial evidence in depth. For context on what private treatment costs and what a legitimate price should include, the treatment options page sets out current pricing without hidden extras. Payday timing, holiday cover and Monday orders are worth thinking about practically: same-day dispatch applies to orders confirmed before 12pm on working days, so planning around bank holidays avoids any gap in supply.

If you are ready to check whether you qualify, start your free consultation and a GPhC-registered prescriber will review your details the same day.